

[Hydroxocobalamin](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.1. Antianaemia medicines](#)

ATC codes: [B03BA03](#)

EMLc

Indication

Megaloblastic anaemia due to vitamin B12 deficiency ICD11 code: [3A01.Z](#)

INN

Hydroxocobalamin

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate) ; 1 mg per mL in 1 mL ampoule (as hydrochloride) ; 1 mg per mL in 1 mL ampoule (as sulfate)

EML status history

First added in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1989 ([TRS 796](#))

Changed in 2007 ([TRS 950](#))

Changed in 2011 ([TRS 965](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Hydroxocobalamin](#)

DrugBank

[Hydroxocobalamin](#)

Summary of evidence and Expert Committee recommendations

Various salts of hydroxocobalamin (acetate, hydrochloride and sulfate) were specified in the listing.